Eli Lilly (LLY) has enjoyed a successful run the past several quarters as the company's blockbuster GLP-1 weight-loss drug ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Explore how Trump's executive orders are impacting Indiana, from DEI to medical research, arts, and housing initiatives, and how Hoosiers are responding.

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we ...

International Business Machines Corp. plans to invest $150 billion in the US over the next five years, joining a cohort of ...

European markets kicked off the week in positive territory, with investors anticipating major earnings and data releases in ...

Trump's 100th Day, April Jobs Report, Inflation Data, First Quarter GDP, Earnings from Microsoft, Meta Platforms, Apple, ...

Since launching its wildly popular weight-loss drug Wegovy in 2021, Novo Nordisk has raised its annual sales guidance several ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...

Private businesses that give away all profits and also succeed as businesses are scarce; the Newman’s Own food branding ...